WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Comprehensive Review of Gastro Retentive Drug Delivery Systems (GRDDS)

Mr. Chinchkar Shreyas[1], Mrs. Maske Deepti[2]

[1,2] YSPM's, Yashoda Technical Campus, Faculty of Pharmacy, Wadhe, Satara
Corresponding author email : shreyaschinchkar@gmail.com

ABSTRACT

Gastro-retentive drug delivery systems (GRDDS) represent an advanced approach in oral drug delivery, designed to prolong the residence time of drugs in the stomach, thereby enhancing their absorption and bioavailability. These systems are particularly beneficial for drugs with a narrow absorption window in the upper gastrointestinal tract, poor stability in the intestinal or colonic environments, or those requiring a prolonged local action in the stomach. Various strategies have been employed to achieve gastro-retention, including high-density systems, low-density floating systems, mucoadhesive systems, expandable systems, and superporous hydrogels. Each approach leverages different mechanisms, such as buoyancy, adhesion to the gastric mucosa, or size expansion, to enhance gastric retention. Key considerations in the design of GRDDS include the physicochemical properties of the drug, gastric motility patterns, and gastric emptying time. Evaluation of GRDDS involves both in vitro and in vivo testing to assess parameters like buoyancy, swelling index, mucoadhesion strength, and actual gastric retention time. While GRDDS offer significant advantages such as improved bioavailability, reduced dosing frequency, and enhanced patient compliance, challenges remain in ensuring consistent performance across diverse patient populations and mitigating potential gastric irritation. Continued research and technological advancements are expected to address these challenges, further refining GRDDS and expanding their clinical applications.

Keywords – GRDDS, GRDDS Use Cases, Importance, Future prospects

Introduction

Gastro retentive drug delivery systems (GRDDS) are innovative drug delivery methods designed to enhance the retention time of drugs in the stomach. This approach improves the bioavailability and therapeutic efficacy of medications with a narrow absorption window in the upper gastrointestinal (GI) tract. GRDDS maintain a controlled release of the drug within the gastric environment for extended periods, which is particularly advantageous for drugs absorbed mainly in the stomach or the upper small intestine.

Gastro-retentive drug delivery systems (GRDDS) are designed to prolong the residence time of a drug in the stomach, enhancing its absorption and bioavailability. This approach is particularly beneficial for drugs that are primarily absorbed in the stomach or upper part of the small intestine, have a narrow absorption window, or are unstable in the intestinal or colonic environments.

Need for Gastroretentive Drug Delivery Systems

1. Improved Bioavailability:

- Certain drugs are absorbed primarily in the stomach or the upper part of the small intestine. Prolonging the gastric retention time ensures that these drugs have more time to be absorbed, improving their bioavailability.

2. Enhanced Therapeutic Efficacy:

- By maintaining a steady concentration of the drug in the stomach over an extended period, GRDDS can provide a more consistent therapeutic effect, reducing the frequency of dosing and improving patient compliance.

3. Localized Drug Delivery:

- For drugs intended to act locally in the stomach, such as those used to treat Helicobacter pylori infections or gastric ulcers, prolonged gastric retention allows the drug to remain at the site of action for an extended period, enhancing its effectiveness.

4. Reduction of Adverse Effects:

- Some drugs cause irritation to the gastric mucosa. GRDDS can help mitigate this by ensuring that the drug is released slowly over time rather than all at once, reducing the likelihood of irritation and adverse effects.

5. Suitability for Drugs with a Narrow Absorption Window:

- Drugs with a narrow absorption window in the gastrointestinal tract benefit from prolonged gastric retention, as this ensures that the drug remains in the optimal absorption zone for a longer duration.

6. Overcoming Limitations of Conventional Dosage Forms:

- Conventional dosage forms may pass through the stomach quickly, limiting the time available for absorption. GRDDS can overcome this limitation by ensuring the drug stays in the stomach longer.

Objectives of Gastroretentive Drug Delivery Systems

1. Prolong Gastric Retention Time:

- Design systems that can float, swell, adhere, or be retained in the stomach, ensuring that the dosage form remains in the stomach for an extended period.

2. Control Drug Release:

- Develop formulations that can release the drug in a controlled manner, either immediately or over a prolonged period, to maintain a consistent therapeutic effect.

3. Enhance Bioavailability:

- Ensure that the drug is available at the site of absorption for an extended period, maximizing the amount of drug that enters the systemic circulation.

4. Reduce Dosing Frequency:

- By maintaining therapeutic drug levels over a longer period, GRDDS can reduce the frequency of dosing, which can improve patient adherence to the medication regimen.

5. Improve Patient Compliance:

- Develop dosage forms that are easy to administer and can provide therapeutic effects over an extended period, reducing the burden on patients to remember multiple doses throughout the day.

6. Achieve Targeted Delivery:

- For drugs that need to act in the stomach or upper gastrointestinal tract, ensure that the drug remains in the desired location for the optimal duration.

7. Minimize Fluctuations in Drug Levels:

- Provide a more stable and consistent drug concentration in the bloodstream, avoiding peaks and troughs that can lead to suboptimal therapy or adverse effects.

By addressing the specific needs of drug delivery to the stomach and upper gastrointestinal tract, GRDDS can significantly enhance the effectiveness of certain medications, improve patient compliance, and minimize side effects.

Mechanisms of GRDDS



Fig. 1 Basic structure of stomach

Various mechanisms are employed to prolong gastric retention:

1. Floating Systems: These systems float on gastric fluids due to their lower density compared to the stomach contents. They can be classified into effervescent and non-effervescent systems.

- **Effervescent Systems:** These contain gas-generating agents like sodium bicarbonate that produce carbon dioxide upon contact with gastric acid, making the dosage form buoyant.

- **Non-effervescent Systems:** These rely on polymers that swell in contact with gastric fluids, reducing their density and allowing them to float.

2. Bioadhesive Systems: These systems use bioadhesive polymers to stick to the stomach lining, increasing the residence time of the dosage form.

3. Swelling and Expanding Systems: These systems expand in size once in the stomach, preventing their passage through the pylorus due to their larger dimension relative to the pyloric opening.

4. High-Density Systems: These systems sink and remain settled in the lower part of the stomach, as their density is higher than that of gastric fluids.

- **Benefits of GRDDS**

1. Enhanced Bioavailability: By retaining the drug in the stomach, GRDDS improve the absorption of drugs absorbed through the gastric mucosa.

2. Sustained Release: GRDDS provide controlled drug release, ensuring prolonged therapeutic effects and reducing dosing frequency.

3. Reduced Side Effects: Maintaining consistent drug concentrations in the bloodstream helps minimize the peaks and troughs associated with conventional dosing, potentially reducing side effects.

4. Targeted Therapy: GRDDS are useful for targeting local conditions in the stomach, such as peptic ulcers or gastritis.

- **Challenges and Considerations**

Despite their advantages, GRDDS face several challenges:

1. Variable Gastric Motility: Differences in gastric emptying rates between individuals and under different physiological conditions can impact GRDDS effectiveness.

2. pH Variability: Fluctuating stomach pH levels can affect the stability and solubility of certain drugs in GRDDS.

3. Patient Compliance: The physical form and size of some GRDDS may affect patient acceptance and adherence to the treatment regimen.

4. Complex Formulation Process: Developing stable and effective GRDDS requires a deep understanding of materials and drug-release kinetics, often involving complex manufacturing processes.

Examples of GRDDS

1. Floating Tablets: Used for drugs like ciprofloxacin and metformin, which benefit from extended gastric retention.

2. Bioadhesive Tablets: Formulations containing polymers like chitosan can adhere to the stomach lining.

3. Swelling Tablets: Drugs such as gabapentin are formulated into swelling tablets to enhance gastric retention and absorption.

Future Perspectives

The development of GRDDS continues to evolve with advancements in materials science and drug formulation technologies. Future trends may include:

1. Smart Polymers: Polymers that respond to environmental stimuli (e.g., pH, temperature) to optimize drug release.

2. Nanotechnology: Using nanoparticles to improve the stability, bioavailability, and targeted delivery of drugs.

3. Personalized Medicine: Tailoring GRDDS formulations to individual patients' physiological conditions to maximize therapeutic outcomes.

Modern applications of GRDDS -

Gastroretentive drug delivery systems (GRDDS) are designed to improve the bioavailability and therapeutic efficacy of drugs by prolonging their residence time in the stomach. These systems are particularly advantageous for drugs that are absorbed primarily in the stomach or upper part of the small intestine, drugs that degrade in the intestinal or colonic environment, and drugs that are intended to act locally in the stomach. Here is a comprehensive review of the various applications of GRDDS:

1. Prolonged Drug Release

Example: Metformin

- Application: Metformin, an anti-diabetic drug, benefits from GRDDS as it is predominantly absorbed in the upper part of the gastrointestinal tract. A gastroretentive system can maintain a steady drug concentration in the stomach, enhancing its bioavailability and reducing dosing frequency .

2. Local Stomach Treatment

Example: Antibiotics for H. pylori

- Application: Helicobacter pylori infection, which causes peptic ulcers, can be more effectively treated with GRDDS. The prolonged presence of antibiotics like amoxicillin in the stomach increases the chances of eradicating the bacteria, leading to better treatment outcomes .

3. Improved Solubility and Absorption

Example: Ranitidine

- Application: Drugs like ranitidine, used for treating gastric ulcers, have improved absorption profiles with GRDDS. These systems allow the drug to stay longer in the stomach, leading to better solubility in the acidic environment and enhanced absorption .

4. Reduced Dosing Frequency

Example: Captopril

- Application: For drugs like captopril, used in hypertension management, GRDDS can provide a more controlled and sustained release, reducing the need for frequent dosing and thereby improving patient compliance .

5. Minimized Drug Degradation

Example: Levodopa

- Application: Levodopa, used in Parkinson's disease, can degrade in the intestinal environment. GRDDS can retain the drug in the stomach, minimizing its degradation and improving therapeutic efficacy .

6. Targeted Delivery

Example: Antacids

- Application: Antacids and other medications intended to act locally in the stomach benefit significantly from GRDDS. By staying longer in the stomach, these drugs can provide prolonged relief from symptoms such as acid reflux and heartburn .

7. Enhanced Bioavailability of Drugs with Narrow Absorption Window

Example: Furosemide

- Application: Drugs like furosemide, which have a narrow absorption window in the gastrointestinal tract, can have enhanced bioavailability with GRDDS. This system ensures that the drug is released slowly and continuously in the stomach, leading to better absorption rates .

Types of Gastroretentive Drug Delivery Systems

1. Floating Systems

These systems float on gastric fluids due to their lower density. Examples include effervescent tablets that release gas upon contact with gastric fluids, forming a floating gel-like barrier.



Fig. 2 In-Situ Gelling system

2. Swelling and Expanding Systems

These systems swell to a size that prevents their passage through the pylorus. They gradually release the drug as they remain buoyant in the stomach.

3. Bio/Mucoadhesive Systems

These systems adhere to the gastric mucosa, thereby increasing gastric residence time and ensuring prolonged drug release.

4. High-Density Systems

These systems have a higher density than gastric fluids and settle at the bottom of the stomach, releasing the drug in a sustained manner.



Fig. 3 High density systems

Design Considerations

- **Physicochemical Properties of the Drug**

1. Solubility and Stability: Drugs suitable for GRDDS should exhibit solubility in gastric fluids and stability in the acidic environment of the stomach.

2. Absorption Window: Drugs with a narrow absorption window in the upper gastrointestinal tract are ideal candidates.
3. Dosage: The drug should be potent enough to be effective in a small dose.

- **Biological Considerations**

1. Gastrointestinal Motility: Understanding the patterns of gastrointestinal motility, including the fasted and fed states, is crucial for designing GRDDS.
2. Gastric Emptying Time: Drugs with a longer gastric emptying time benefit more from GRDDS.

- **Formulation Strategies**

- **High-Density Systems**

High-density systems sink to the bottom of the stomach and resist the peristaltic movements, thereby prolonging gastric retention. These systems often involve incorporating excipients like barium sulfate, zinc oxide, titanium dioxide, and iron powder to increase the density of the dosage form.

- **Low-Density Systems**

Low-density systems, such as floating tablets and capsules, remain buoyant on the gastric fluids. Common approaches include:
1. Effervescent Systems: These utilize a combination of gas-generating agents (like sodium bicarbonate and citric acid) and swellable polymers to ensure buoyancy.
2. Non-Effervescent Systems: These systems use matrix-forming polymers like hydroxypropyl methylcellulose (HPMC), polyethylene oxide, and ethyl cellulose to maintain buoyancy through swelling and gel formation.

- **Mucoadhesive Systems**

Mucoadhesive systems adhere to the gastric mucosa, extending the drug's residence time. Polymers such as chitosan, carbopol, and alginate are frequently used due to their mucoadhesive properties.

- **Expandable Systems**

Expandable systems increase in size after ingestion to prevent passage through the pylorus. These systems are often made using swellable polymers that expand upon contact with gastric fluids. Examples include superporous hydrogels and unfolding polymeric films.

- **Superporous Hydrogels**

These hydrogels can absorb significant amounts of gastric fluid and expand rapidly, providing an extended release profile. They are particularly advantageous due to their rapid swelling properties, which ensure immediate expansion and prolonged gastric retention.

Evaluation Parameters

- **In Vitro Testing**

1. Buoyancy Studies: Assesses the floating lag time and duration.
2. Swelling Index: Measures the extent and rate of swelling of the dosage form.
3. Mucoadhesion Strength: Evaluates the adhesion strength of the formulation to gastric mucosa.

- **In Vivo Testing**

1. Gastric Retention Time: Determines the actual residence time of the dosage form in the stomach using imaging techniques like X-ray or gamma scintigraphy.
2. Pharmacokinetic Studies: Evaluates the drug's absorption profile, bioavailability, and plasma concentration over time.

Advantages and Challenges

- **Advantages**

1. Improved Bioavailability: Enhanced absorption for drugs with a narrow absorption window.
2. Reduced Dosing Frequency: Extended release formulations can reduce the need for frequent dosing.
3. Enhanced Patient Compliance: Reduced dosing frequency and improved therapeutic efficacy enhance patient compliance.

- **Challenges**

1. Variability in Gastric Retention: Differences in gastric motility and emptying rates among individuals can affect the performance of GRDDS.
2. Complex Formulation Process: Designing systems that consistently achieve the desired retention and release profiles can be challenging.

3. Potential for Irritation: Prolonged retention of some formulations may irritate the gastric mucosa.

Conclusion

Gastro retentive drug delivery systems offer a promising approach for improving the therapeutic efficacy of certain drugs by prolonging their gastric residence time. Despite development and implementation challenges, ongoing research and technological advancements have the potential to overcome these hurdles and enhance the effectiveness of these systems. Gastroretentive drug delivery systems hold significant promise in improving the efficacy and convenience of various drugs, particularly those with specific absorption characteristics or those intended for local action in the stomach. By optimizing drug release profiles and enhancing bioavailability, GRDDS can lead to better patient outcomes and compliance.

The formulation of gastro-retentive drug delivery systems involves a multi-faceted approach that takes into account the physicochemical properties of the drug, biological considerations, and various formulation strategies. Despite the challenges, GRDDS offer significant advantages in terms of enhanced bioavailability and improved patient compliance, making them a valuable tool in modern pharmaceutics. Future research and technological advancements will likely further refine these systems, expanding their applicability and effectiveness.

This review presents an in-depth analysis of gastro retentive drug delivery systems, highlighting their mechanisms, benefits, challenges, and future directions. It underscores the potential of GRDDS to significantly improve drug therapy by optimizing the pharmacokinetic and pharmacodynamic profiles of medications.

REFERENCES:

1. Desai, S., Bolton, S. (1993). A Floating Controlled-Release Drug Delivery System: In Vitro-In Vivo Evaluation. Pharm Res, 10, 1321–1325.
2. Groning, R., Heun, G. (1984). Oral dosage forms with controlled gastrointestinal transit. Drug Dev Ind Pharm, 10, 527–539.
3. Streubel, A., Siepmann, J., Bodmeier, R. (2006). Gastroretentive drug delivery systems. Expert Opin Drug Deliv, 3, 217-233.
4. Whitehead, L., Fell, J.T., Collett, J.H., Sharma, H.L., Smith, A.M. (1998). Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. J Control Release, 55, 3-12.
5. Hirtz, J. (1985). The gastrointestinal absorption of drugs in man: a review of current concepts and methods of investigation. Br J Clin Pharmacol, 19, 77S-83S.
6. Bardonnet, P.L., Faivre, V., Pugh, W.J., Piffaretti, J.C., Falson, F. (2006). Gastroretentive dosage forms: overview and special case of Helicobacter pylori. J Control Release, 111, 1-18.
7. Rouge, N., Buri, P., Doelker, E. (1996). Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int J Pharm, 136, 117-139.